Anteris Technologies (NasdaqGM:AVR) FY Conference March 10, 2026 01:30 PM ET Company ParticipantsWayne Paterson - CEOConference Call ParticipantsMatt Miksic - Medical Supplies and Devices Research AnalystMatt MiksicWell, good afternoon, everybody. Thanks for joining us. Very pleased to have with us Anteris Technologies, Wayne Paterson, CEO and founder, and there's a number of other roles and adjectives that I put behind that. Advocates, you know, of what's become, you know, the one of the promising TAVR val ...

Anteris Technologies (NasdaqGM:AVR) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsWayne Paterson - CEOConference Call ParticipantsJosh Jennings - Managing Director and Senior Research AnalystJosh JenningsGood afternoon. I'm Josh Jennings from the TD Cowen Medical Devices research team. We are excited to have the CEO of Anteris, Wayne Paterson, here in Boston live, for a fireside chat. Wayne, great to see you in person. Thank you for making the trip and participating in our conference.Wayne Pa ...

The attached Form 10-K Annual Report for the year ended 31 December 2025 has been filed with the U.S. Securities and Exchange Commission. It includes the consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and are denominated in U.S. dollars. Exhibit 99.1 Results for announcement to the market | Name of entity: | Anteris Technologies Global Corp. ("ATGC") | | --- | --- | | ARBN: | 677 960 235 | | ...

Core Insights - Anteris Technologies reported significant advancements in 2025, focusing on the development of the DurAVR transcatheter heart valve (THV) and positioning itself for leadership in the structural heart market [3][4]. Financial Performance - The company's net operating cash outflows for 2025 were $77.8 million, reflecting increased clinical, regulatory, and manufacturing requirements to support the PARADIGM Trial [4]. - Research and Development (R&D) expenses totaled $69.1 million, which included costs for manufacturing upscaling, clinical trial preparations, and an increase in R&D personnel [6]. - Selling, general, and administrative expenses were reported at $26.1 million [6]. Clinical Developments - Anteris initiated the global pivotal PARADIGM Trial, building on prior experience treating 130 patients with the DurAVR THV, including complex cases [5]. - The company received FDA Investigational Device Exemption (IDE) approval in Q4 2025 to commence the PARADIGM Trial in the U.S. [5]. - The PARADIGM Trial aims to enroll approximately 1,000 patients to evaluate the safety and effectiveness of the DurAVR THV compared to existing transcatheter aortic valve replacements (TAVRs) [8]. Strategic Initiatives - Anteris completed capital raises totaling $320 million in early 2026, including a strategic investment from Medtronic to support the PARADIGM Trial and advance global commercialization of the DurAVR THV System [5]. - The company strengthened its operational infrastructure and advanced its quality management system, achieving ISO 13485 certification for DurAVR THV production [5]. Product Overview - The DurAVR THV is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy human aortic valve [11]. - The valve is made from Anteris' patented ADAPT tissue, which has been clinically used for over 10 years and is FDA-cleared [11].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-42437 Anteris Technologies Global Corp. (Exact name of Registrant as specified in its Charter) Delaware 99-1407174 (State or other ju ...

Core Viewpoint - Anteris Technologies Global Corp. is actively participating in two major healthcare conferences, showcasing its commitment to advancing medical devices for heart function restoration [1][4]. Group 1: Conference Details - Anteris will present at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, featuring a fireside chat with analyst Joshua Jennings [2]. - The Barclays 28th Annual Healthcare Conference will take place on March 10, 2026, with a fireside chat led by analyst Matt Miksic [3]. - Both conferences will include 1x1 meetings and will be accessible via webcasts, which will be archived for up to 90 days [2][3]. Group 2: Company Overview - Anteris Technologies is a global structural heart company focused on designing and commercializing innovative medical devices [4]. - The company is headquartered in Australia and has a significant operational presence in Minneapolis, USA, emphasizing a science-driven approach [4]. - Anteris' lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [5].

Group 1 - Lake Street analyst Frank Takkinen lowered the price target on Anteris Technologies (AVR) to $15 from $20 while maintaining a Buy rating on the shares [1] - The $320 million in gross financing, which included a $90 million strategic investment from Medtronic (MDT), is described as "a transformational deal for Anteris" [1] - The financing is said to relieve the capital overhang, verify the product's viability, and entrench Medtronic as a collaborator and potential acquirer [1]

Core Viewpoint - Anteris Technologies has secured a $90 million strategic investment from Medtronic, which follows a $320 million underwritten offering of common stock, aimed at advancing the global pivotal PARADIGM trial and commercializing the DurAVR® Transcatheter Heart Valve [1][3]. Group 1: Investment and Collaboration - The investment from Medtronic is seen as a significant milestone for Anteris, validating its program in the capital markets and indicating potential future collaborations [3]. - Anteris and Medtronic share a vision of advancing the Transcatheter Aortic Valve Replacement (TAVR) market through improved clinical science and valve design, focusing on durability and long-term patient outcomes [2][3]. Group 2: PARADIGM Trial - The PARADIGM Trial is a randomized controlled trial designed to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVR options, with an enrollment target of approximately 1,000 patients [4][5]. - The trial will assess non-inferiority based on a primary composite endpoint that includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure [5]. - Recruitment for the PARADIGM Trial has already begun, with the first patients enrolled in the fourth quarter of 2025 [6]. Group 3: Product Overview - Anteris' lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy aortic valve [8]. - The DurAVR® THV is constructed from Anteris' patented ADAPT® tissue technology, which has been clinically used for over 10 years and is FDA-cleared, having been distributed to over 55,000 patients globally [8].

Core Viewpoint - Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at a price of $5.75 per share, alongside a private placement of 15.65 million shares to Medtronic, raising approximately $320 million in total gross proceeds [1][2][3]. Group 1: Offering Details - The public offering included the full exercise of underwriters' options to purchase additional shares, with shares sold at $5.75 each [1]. - The private placement involved the sale of shares to Medtronic plc at the same price of $5.75 per share [2]. - The gross proceeds from both the Offering and the Private Placement are approximately $320 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the Offering and Private Placement will support the next stage of growth, including the DurAVR® Transcatheter Heart Valve global pivotal trial for severe aortic stenosis patients [5]. - Funds will also be allocated to expand manufacturing capabilities and support ongoing research and development for v2vmedtech, inc., with remaining amounts designated for working capital and general corporate purposes [5]. Group 3: Financial Management - Barclays, Wells Fargo Securities, and Cantor acted as joint book-running managers for the Offering, while Wells Fargo Securities served as the sole placement agent for the private placement [4]. - The Offering was conducted under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - Smart Logistics Global Limited (SLGB) is up 198% at $3.67 [3] - Brand Engagement Network, Inc. (BNAI) is up 67% at $10.29 [3] - Boxlight Corporation (BOXL) is up 56% at $1.96 [3] - Moolec Science SA (MLEC) is up 51% at $6.64 [3] - Anteris Technologies Global Corp. (AVR) is up 15% at $6.63 [3] - Hycroft Mining Holding Corporation (HYMC) is up 10% at $47.20 [3] - Nathan's Famous, Inc. (NATH) is up 8% at $100.94 [3] - Progress Software Corporation (PRGS) is up 6% at $41.05 [3] - LightPath Technologies, Inc. (LPTH) is up 5% at $14.81 [3] - ZenaTech, Inc. (ZENA) is up 5% at $4.33 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) is down 29% at $3.81 [4] - Solo Brands, Inc. (SBDS) is down 21% at $5.25 [4] - GlucoTrack, Inc. (GCTK) is down 19% at $3.07 [4] - Galaxy Payroll Group Limited (GLXG) is down 19% at $2.26 [4] - INVO Fertility, Inc. (IVF) is down 13% at $2.04 [4] - Black Titan Corporation (BTTC) is down 11% at $2.11 [4] - Envirotech Vehicles, Inc. (EVTV) is down 10% at $3.30 [4] - Erasca, Inc. (ERAS) is down 6% at $9.21 [4] - ENDRA Life Sciences Inc. (NDRA) is down 6% at $4.31 [4] - Bonk, Inc. (BNKK) is down 6% at $3.74 [4]